Translating basic science insight into public health action for multidrug- and extensively drug-resistant tuberculosis

Respirology

Volumn 17, Issue 5, 2012, Pages 772-791

  Walter, Nicholas D ^a   Strong, Michael ^b   Belknap, Robert ^c   Ordway, Diane J ^e   Daley, Charles L ^b   Chan, Edward D ^a,b,d  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

^c DENVER PUBLIC HEALTH   (United States)

^d Veterans Affairs ^*  (United States)

^e Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

extensively drug resistant tuberculosis diagnosis; extensively drug resistant tuberculosis epidemiology*; extensively drug resistant tuberculosis prevention control; multidrug resistant diagnosis; multidrug resistant epidemiology; tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

DRUG SCREENING; DRUG SENSITIVITY; DRUG TARGETING; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; IMMUNE STATUS; MIXED INFECTION; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUBLIC HEALTH; REINFECTION; REVIEW; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; DRUG DISCOVERY; HUMANS; PUBLIC HEALTH; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84862988458     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02176.x     Document Type: Review

References (189)

1. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. 2010.
2. Van Rie A, Enarson D,. XDR tuberculosis: an indicator of public-health negligence. Lancet 2006; 368: 1554-6. (Pubitemid 44691898)
3. Frieden TR, Sterling T, Pablos-Mendez A, et al,. The emergence of drug-resistant tuberculosis in New York City. N. Engl. J. Med. 1993; 328: 521-6. (Pubitemid 23053827)
4. Shah NS, Richardson J, Moodley P, et al,. Increasing drug resistance in extensively drug-resistant tuberculosis, South Africa. Emerg. Infect. Dis. 2011; 17: 510-13.
5. Velayati AA, Masjedi MR, Farnia P, et al,. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009; 136: 420-5.
6. Udwadia ZF, Amale RA, Ajbani KK, et al,. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis. 2012; 54: 579-81.
7. World Health Organization. Tuberculosis that is 'resistant to all drugs': frequently asked questions. 2012. [Accessed 6 April 2012.] Available from URL
8. Chiang C-Y, Centis R, Migliori GB,. Drug-resistant tuberculosis: past, present, future. Respirology 2010; 15: 413-32.
9. Crofton J, Mitchison DA,. Streptomycin resistance in pulmonary tuberculosis. Br. Med. J. 1948; 2: 1009-15.
10. Medical Research Council. Treatment of pulmonary tuberculosis with isoniazid. Br. Med. J. 1952; 2: 735-46.
11. Ogilvie CM,. Bacterial resistance to isoniazid and 'marsilid' in treatment of pulmonary tuberculosis. Br. Med. J. 1954; 2: 829-33.
12. Pyle MM,. Relative numbers of resistant tubercle bacilli in sputa of patients before and during treatment with streptomycin. Mayo Clin. Proc. 1947; 22: 465-73.
13. Cegielski JP,. Extensively drug-resistant tuberculosis: 'There must be some kind of way out of here'. Clin. Infect. Dis. 2010; 50: S195-200.
14. Shah NS, Wright A, Bai G-H, et al,. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 2007; 13: 380-7. (Pubitemid 46348124)
15. World Health Organization. Global tuberculosis control: WHO report 2011. 2011.
16. Glaziou P, Floyd K, Korenromp EL, et al,. Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. Bull. World Health Organ. 2011; 89: 573-82.
17. World Health Organization. Consolidated action plan to prevent and combat multidrug- and extensively drug-resistant tuberculosis in the WHO European Region 2011-2015. 2011.
18. Van Deun A, Martin A, Palomino JC,. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int. J. Tuberc. Lung Dis. 2010; 14: 131-40.
19. Moore DAJ, Shah NS,. Alternative methods of diagnosing drug resistance: what can they do for me? J. Infect. Dis. 2011; 204: S1110-19.
20. Small PM, Pai M,. Tuberculosis diagnosis-time for a game change. N. Engl. J. Med. 2010; 363: 1070-1.
21. Helb D, Jones M, Story E, et al,. Rapid Detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J. Clin. Microbiol. 2010; 48 (1): 229-37.
22. Boehme CC, Nabeta P, Hillemann D, et al,. Rapid molecular detection of tuberculosis and rifampin resistance. N. Engl. J. Med. 2010; 363: 1005-15.
23. Boehme CC, Nicol MP, Nabeta P, et al,. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377: 1495-505.
24. Sterling TR, Pham PA, Chaisson RE,. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin. Infect. Dis. 2010; 50 (Suppl. 3): S223-30.
25. Nicol MP, Workman L, Isaacs W, et al,. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect. Dis. 2011; 11: 819-24.
26. Trebucq A, Enarson DA, Chiang CY, et al,. Xpert MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int. J. Tuberc. Lung Dis. 2011; 15: 1567-71.
27. Smith SE, Kurbatova EV, Cavanaugh JS, et al,. Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis. Int. J. Tuberc. Lung Dis. 2012; 16: 203-5.
28. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampin resistance: Xpert MTB/RIF system. Policy Statement 2011.
29. World Health Organization. WHO monitoring of Xpert MTB/RIF roll-out. 2011. [Accessed 15 December 2011.] Available from URL:.
30. Morgan M, Kalantri S, Flores L, et al,. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect. Dis. 2005; 5: 62.
31. Albert H, Bwanga F, Mukkada S, et al,. Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC Infect. Dis. 2010; 10: 41.
32. Barnard M, Albert H, Coetzee G, et al,. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am. J. Respir. Crit. Care Med. 2008; 177: 787-92. (Pubitemid 351490566)
33. Orenstein EW, Basu S, Shah NS, et al,. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect. Dis. 2009; 9: 153-61.
34. Keshavjee S, Seung K,. Stemming the Tide of Multidrug Resistant Tuberculosis: Major Barriers to Addressing the Growing Epidemic. Institute of Medicine, Washington, DC, 2009.
35. Mitnick CD, Castro KG, Harrington M, et al,. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med. 2007; 4: e292.
36. Shin SS, Keshavjee S, Gelmanova IY, et al,. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am. J. Respir. Crit. Care. Med. 2010; 182: 426-32.
37. Campbell PJ, Morlock GP, Sikes RD, et al,. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2011; 55: 2032-41.
38. Louw GE, Warren RM, Gey van Pittius NC, et al,. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care. Med. 2011; 184: 269-76.
39. Lin S-YG, Probert W, Lo M, et al,. Rapid detection of isoniazid and rifampin resistance mutations in Mycobacterium tuberculosis complex from cultures or smear-positive sputa by use of molecular beacons. J. Clin. Microbiol. 2004; 42: 4204-8. (Pubitemid 39296145)
40. Davies J, Davies D,. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 2010; 74: 417-33.
41. Pérez-Osorio AC, Boyle DS, Ingham ZK, et al,. Rapid identification of mycobacteria and drug resistant Mycobacterium tuberculosis using a single multiplex PCR and DNA sequencing. J. Clin. Microbiol. 2012; 50: 326-36.
42. Ioerger TR, Koo S, No E-G, et al,. Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa. PLoS ONE 2009; 4: e7778.
43. Koenig R,. Few mutations divide some drug-resistant TB strains. Science 2007; 318: 901-2. (Pubitemid 350098961)
44. Sandgren A, Strong M, Muthukrishnan P, et al,. Tuberculosis drug resistance mutation database. PLoS Med. 2009; 6: e1000002.
45. Swedish Research Council. TB drug resistance mutation database. 2011. [Accessed 6 April 2012.] Available from URL
46. Gillespie SH,. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob. Agents Chemother. 2002; 46: 267-74. (Pubitemid 34087167)
47. Dye C,. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nat. Rev. Microbiol. 2009; 7: 81-7.
48. O'Sullivan DM, McHugh TD, Gillespie SH,. Mapping the fitness of Mycobacterium tuberculosis strains: a complex picture. J. Med. Microbiol. 2010; 59: 1533-5.
49. Gagneux S, Long CD, Small PM, et al,. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312: 1944-6. (Pubitemid 43993719)
50. Jenkins C, Bacon J, Allnutt J, et al,. Enhanced heterogeneity of rpoB in Mycobacterium tuberculosis found at low pH. J. Antimicrob. Chemother. 2009; 63: 1118-20.
51. Comas I, Borrell S, Roetzer A, et al,. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 2012; 44: 106-10.
52. Richardson ET, Lin SYG, Pinsky BA, et al,. First documentation of isoniazid reversion in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 2009; 13: 1347-54.
53. Gardy JL, Johnston JC, Sui SJH, et al,. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N. Engl. J. Med. 2011; 364: 730-9.
54. David HL,. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl. Microbiol. 1970; 20: 810-14.
55. Ford CB, Lin PL, Chase MR, et al,. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat. Genet. 2011; 43: 482-6.
56. Kaplan G, Post FA, Moreira AL, et al,. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect. Immun. 2003; 71: 7099-108. (Pubitemid 37475342)
57. Rachman H, Strong M, Ulrichs T, et al,. Unique transcriptome signature of Mycobacterium tuberculosis in pulmonary tuberculosis. Infect. Immun. 2006; 74: 1233-42. (Pubitemid 43185563)
58. Rodrigues L, Machado D, Couto I, et al,. Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect. Genet. Evol. 2012; 12: 695-700.
59. da Silva PEA, Von Groll A, Martin A, et al,. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol. Med. Microbiol. 2011; 63: 1-9.
60. Foundation for Innovative New Diagnostics. TB diagnostics pipeline. 2012. [Accessed 6 April 2012.] Available from URL
61. Stead WW,. Pathogenesis of a first episode of chronic tuberculosis in man: recrudescence of residuals of the primary infection or exogenous reinfection? Am. Rev. Respir. Dis. 1967; 95: 729-45.
62. Lurie MB,. Native and acquired resistance to tuberculosis. Am. J. Med. 1950; 9: 591-610.
63. Karns JR,. Tuberculin sensitivity and tuberculosis in nursing and medical students. Dis. Chest 1961; 40: 291-301.
64. Flahiff EW,. The occurrence of tuberculosis in persons who failed to react to tuberculin, and in persons with positive tuberculin reaction. Am. J. Epidemiol. 1939; 30 (Section B): 69-74.
65. Zeigler JE, Edwards ML, Smith DW,. Exogenous reinfection in experimental airborne tuberculosis. Tubercle 1985; 66: 121-8. (Pubitemid 15011390)
66. Chiang C-Y, Riley LW,. Exogenous reinfection in tuberculosis. Lancet Infect. Dis. 2005; 5: 629-36. (Pubitemid 41383908)
67. Vynnycky E, Fine PEM,. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol. Infect. 1997; 119: 183-201. (Pubitemid 27474799)
68. Feng Z, Castillo-Chavez C, Capurro AF,. A model for tuberculosis with exogenous reinfection. Theor. Popul. Biol. 2000; 57: 235.
69. Colijn C, Cohen T, Murray M,. Latent coninfection and the maintenance of strain diversity. Bull. Math. Biol. 2009; 71: 247-63.
70. Houben RMGJ, Glynn JR, Mallard K, et al,. Human immunodeficiency virus increases the risk of tuberculosis due to recent re-infection in individuals with latent infection. Int. J. Tuberc. Lung Dis. 2010; 14: 909-15.
71. Bishai JD, Bishai WR, Bishai DM,. Heightened vulnerability to MDR-TB epidemics after controlling drug-susceptible TB. PLoS ONE 2010; 5: e12843.
72. Basu S, Orenstein E, Galvani AP,. The theoretical influence of immunity between strain groups on the progression of drug-resistant tuberculosis epidemics. J. Infect. Dis. 2008; 198: 1502-13.
73. von Reyn CF, Horsburgh CR,. Reinfection with Mycobacterium tuberculosis. Am. J. Respir. Crit. Care. Med. 2006; 173: 133-4.
74. Barry CE, Boshoff HI, Dartois V, et al,. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 2009; 7: 845-55.
75. Anonymous. Is reinfection of tuberculosis from within or without? Lancet 1923; 202: 130.
76. Fenn RM,. Reinfection in tuberculosis. Lancet 1920; 195: 288.
77. Burrell LST,. Reinfection in tuberculosis. Tubercle 1934; 16: 145-52.
78. Kato-Maeda M, Metcalfe JZ, Flores L,. Genotyping of Mycobacterium tuberculosis: application in epidemiologic studies. Future Microbiol. 2011; 6: 203-16.
79. Raleigh JW, Wichelhausen R,. Exogenous reinfection with Mycobacterium tuberculosis confirmed by phage typing. Am. Rev. Respir. Dis. 1973; 108: 639-42.
80. Small PM, Shafer RW, Hopewell PC, et al,. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N. Engl. J. Med. 1993; 328: 1137-44. (Pubitemid 23105750)
81. Martín A, Herranz M, Navarro Y, et al,. Evaluation of the inaccurate assignment of mixed infections by Mycobacterium tuberculosis as exogenous reinfection and analysis of the potential role of bacterial factors in reinfection. J. Clin. Microbiol. 2011; 49: 1331-8.
82. Caminero JA, Pena MJ, Campos-Herrero MI, et al,. Exogenous reinfection with tuberculosis on a European island with a moderate incidence of disease. Am. J. Respir. Crit. Care. Med. 2001; 163: 717-20. (Pubitemid 32230835)
83. Pascopella L, DeRiemer K, Watt JP, et al,. When tuberculosis comes back: who develops recurrent tuberculosis in California? PLoS ONE 2011; 6: e26541.
84. Jasmer RM, Bozeman L, Schwartzman K, et al,. Recurrent tuberculosis in the United States and Canada. Am. J. Respir. Crit. Care. Med. 2004; 170: 1360-6. (Pubitemid 39657201)
85. Bandera A, Gori A, Catozzi L, et al,. Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. J. Clin. Microbiol. 2001; 39: 2213-18. (Pubitemid 32531483)
86. Narayanan S, Swaminathan S, Supply P, et al,. Impact of HIV infection on the recurrence of tuberculosis in South India. J. Infect. Dis. 2010; 201: 691-703.
87. Dobler CC, Crawford ABH, Jelfs PJ, et al,. Recurrence of tuberculosis in a low-incidence setting. Eur. Respir. J. 2009; 33: 160-7.
88. de Boer AS, Borgdorff MW, Vynnycky E, et al,. Exogenous re-infection as a cause of recurrent tuberculosis in a low-incidence area. Int. J. Tuberc. Lung Dis. 2003; 7: 145-52. (Pubitemid 36172675)
89. Verver S, Warren RM, Beyers N, et al,. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am. J. Respir. Crit. Care. Med. 2005; 171: 1430-5. (Pubitemid 40800517)
90. Crampin AC, Mwaungulu JN, Mwaungulu FD, et al,. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS 2010; 24: 417-26.
91. Charalambous S, Grant AD, Moloi V, et al,. Contribution of reinfection to recurrent tuberculosis in South African gold miners. Int. J. Tuberc. Lung Dis. 2008; 12: 942-8.
92. van Rie A, Warren R, Richardson M, et al,. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N. Engl. J. Med. 1999; 341: 1174-9. (Pubitemid 29480655)
93. van Rie A, Victor TC, Richardson M, et al,. Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am. J. Respir. Crit. Care. Med. 2005; 172: 636-42. (Pubitemid 41232977)
94. Uys PW, van Helden PD, Hargrove JW,. Tuberculosis reinfection rate as a proportion of total infection rate correlates with the logarithm of the incidence rate: a mathematical model. J. R. Soc. Interface 2009; 6: 11-15.
95. Wang J-Y, Lee L-N, Lai H-C, et al,. Prediction of the tuberculosis reinfection proportion from the local incidence. J. Infect. Dis. 2007; 196: 281-8. (Pubitemid 47047468)
96. Korenromp EL, Scano F, Williams BG, et al,. Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review. Clin. Infect. Dis. 2003; 37: 101-12. (Pubitemid 36836652)
97. Andrews JR, Gandhi NR, Moodley P, et al,. Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J. Infect. Dis. 2008; 198: 1582-9.
98. Garcia de Viedma D, Marin M, Hernangomez S, et al,. Tuberculosis recurrences: reinfection plays a role in a population whose clinical/ epidemiological characteristics do not favor reinfection. Arch. Intern. Med. 2002; 162: 1873-9.
99. Nunn AJ, Phillips PPJ, Mitchison DA,. Timing of relapse in short-course chemotherapy trials for tuberculosis [Short communication]. Int. J. Tuberc. Lung Dis. 2010; 14: 241-2.
100. Braden CR, Morlock GP, Woodley CL, et al,. Simultaneous infection with multiple strains of Mycobacterium tuberculosis. Clin. Infect. Dis. 2001; 33: e42-7.
101. Bates JH, Stead WW, Rado TA,. Phage type of tubercle bacilli isolated from patients with two or more sites of organ involvment. Am. Rev. Respir. Dis. 1976; 114: 353-8.
102. Mankiewicz E, Liivak M,. Phage types of Mycobacterium tuberculosis in cultures isolated from Eskimo patients. Am. Rev. Respir. Dis. 1975; 111: 307-12.
103. Yeh RW, Hopewell P, Daley CL,. Simultaneous infection with two strains of Mycobacterium tuberculosis identified by restriction fragment length polymorphism analysis. Int. J. Tuberc. Lung Dis. 1999; 3: 537-9. (Pubitemid 29260169)
104. García de Viedma D, Marín M, Ruiz Serrano MJ, et al,. Polyclonal and compartmentalized infection by Mycobacterium tuberculosis in patients with both respiratory and extrarespiratory involvement. J. Infect. Dis. 2003; 187: 695-9. (Pubitemid 36250037)
105. Cohen T, Wilson D, Wallengren K, et al,. Mixed-strain Mycobacterium tuberculosis infections among patients dying in a hospital in KwaZulu-Natal, South Africa. J. Clin. Microbiol. 2011; 49: 385-8.
106. Benedetti A, Menzies D, Behr MA, et al,. How close is close enough? Exploring matching criteria in the estimation of recent transmission of tuberculosis. Am. J. Epidemiol. 2010; 172: 318-26.
107. García de Viedma D, Alonso Rodriguez N, Andrés S, et al,. Characterization of clonal complexity in tuberculosis by mycobacterial interspersed repetitive unit-variable-number tandem repeat typing. J. Clin. Microbiol. 2005; 43: 5660-4. (Pubitemid 41612345)
108. Behr MA,. Polyclonal tuberculosis and the emergence of drug resistance. Am J Resp. Crit. Care 2005; 172: 521-2. (Pubitemid 41232962)
109. Navarro Y, Herranz M, Pérez-Lago L, et al,. Systematic survey of clonal complexity in tuberculosis at a population level and detailed characterization of the isolates involved. J. Clin. Microbiol. 2011; 49: 4131-7.
110. Mallard K, McNerney R, Crampin AC, et al,. Molecular detection of mixed infections of Mycobacterium tuberculosis strains in sputum samples from patients in Karonga District, Malawi. J. Clin. Microbiol. 2010; 48: 4512-18.
111. Shamputa I, Jugheli L, Sadradze N, et al,. Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia. Respir. Res. 2006; 7: 99.
112. Martín A, Herranz M, Ruiz Serrano MJ, et al,. The clonal composition of Mycobacterium tuberculosis in clinical specimens could be modified by culture. Tuberculosis 2010; 90: 201-7.
113. Warren RM, Victor TC, Streicher EM, et al,. Patients with active tuberculosis often have different strains in the same sputum specimen. Am. J. Respir. Crit. Care. Med. 2004; 169: 610-14. (Pubitemid 38270897)
114. Huang H-Y, Tsai Y-S, Lee J-J, et al,. Mixed infection with Beijing and non-Beijing strains and drug resistance pattern of Mycobacterium tuberculosis. J. Clin. Microbiol. 2010; 48: 4474-80.
115. Dickman K, Nabyonga L, Kateete D, et al,. Detection of multiple strains of Mycobacterium tuberculosis using MIRU-VNTR in patients with pulmonary tuberculosis in Kampala, Uganda. BMC Infect. Dis. 2010; 10: 349.
116. Das S, Narayanan S, Hari L, et al,. Simultaneous infection with multiple strains of Mycobacterium tuberculosis identified by restriction fragment length polymorphism analysis. Int. J. Tuberc. Lung Dis. 2004; 8: 267-70. (Pubitemid 38622938)
117. Sergeev R, Colijn C, Cohen T,. Models to understand the population-level impact of mixed strain M. tuberculosis infections. J. Theor. Biol. 2011; 280: 88-100.
118. Comas I, Gagneux S,. A role for systems epidemiology in tuberculosis research. Trends Microbiol. 2011; 19: 492-500.
119. Doherty MT, Wallis RS, Zumla A, et al,. Biomarkers for tuberculosis disease status and diagnosis. Curr. Opin. Pulm. Med. 2009; 15: 181-7.
120. Kirschner MW,. The meaning of systems biology. Cell 2005; 121: 503-4. (Pubitemid 40720002)
121. Berry MPR, Graham CM, McNab FW, et al,. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973-9.
122. Fauci AS, Group tNTW. Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases research agenda and recommendations for priority research. J. Infect. Dis. 2008; 197: 1493-8. (Pubitemid 351706477)
123. Shang S, Harton M, Tamayo MH, et al,. Increased Foxp3 expression in guinea pigs infected with W-Beijing strains of M. tuberculosis. Tuberculosis 2011; 91: 378-85.
124. Ordway D, Henao-Tamayo M, Harton M, et al,. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J. Immunol. 2007; 179: 522-31. (Pubitemid 46986569)
125. Ordway D, Palanisamy G, Henao-Tamayo M, et al,. The cellular immune response to Mycobacterium tuberculosis infection in the guinea pig. J. Immunol. 2007; 179: 2532-41.
126. Mokrousov I,. Genetic geography of Mycobacterium tuberculosis Beijing genotype: a multifacet mirror of human history? Infect. Genet. Evol. 2008; 8: 777-85.
127. Anonymous. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg. Infect. Dis. 2006; 12: 736-43.
128. Cowley D, Govender D, February B, et al,. Recent and rapid emergence of W-Beijing strains of Mycobacterium tuberculosis in Cape Town, South Africa. Clin. Infect. Dis. 2008; 47: 1252-9.
129. van der Spuy GD, Kremer K, Ndabambi SL, et al,. Changing Mycobacterium tuberculosis population highlights clade-specific pathogenic characteristics. Tuberculosis (Edinb.) 2009; 89: 120-5.
130. Ghebremichael S, Groenheit R, Pennhag A, et al,. Drug Resistant Mycobacterium tuberculosis of the Beijing genotype does not spread in Sweden. PLoS ONE 2010; 5: e10893.
131. Hanekom M, Gey van Pittius NC, McEvoy C, et al,. Mycobacterium tuberculosis Beijing genotype: a template for success. Tuberculosis 2011; 91: 510-23.
132. Parwati I, van Crevel R, van Soolingen D,. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect. Dis. 2010; 10: 103-11.
133. Ebrahimi-Rad M, Bifani P, Martin C, et al,. Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family. Emerg. Infect. Dis. 2003; 9: 838-45. (Pubitemid 36801585)
134. Werngren J, Hoffner SE,. Drug-susceptible Mycobacterium tuberculosis Beijing genotype does not develop mutation-conferred resistance to rifampin at an elevated rate. J. Clin. Microbiol. 2003; 41: 1520-4. (Pubitemid 36428098)
135. Ioerger T, Feng Y, Chen X, et al,. The non-clonality of drug resistance in Beijing-genotype isolates of Mycobacterium tuberculosis from the Western Cape of South Africa. BMC Genomics 2010; 11: 670.
136. Kremer K, van-der-Werf MJ, Au BK, et al,. Vaccine-induced immunity circumvented by typical Mycobacterium tuberculosis Beijing strains. Emerg. Infect. Dis. 2009; 15: 335-9.
137. Ordway DJ, Sonnenberg MG, Donahue SA, et al,. Drug-resistant strains of Mycobacterium tuberculosis exhibit a range of virulence for mice. Infect. Immun. 1995; 63: 741-3.
138. Ordway DJ, Shang S, Henao-Tamayo M, et al,. Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells. Clin. Vaccine Immunol. 2011; 18: 1527-35.
139. Lenaerts AJ, Degroote MA, Orme IM,. Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol. 2008; 16: 48-54.
140. De Groote MA, Gruppo V, Woolhiser LK, et al,. Importance of confirming in vivo efficacy data of novel antibacterial drug regimens agains various strains of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2012; 56: 731-8.
141. Orme IM,. Virulence of recent notorious Mycobacterium tuberculosis isolates. Tuber. Lung Dis. 1999; 79: 379-81.
142. Lopez B, Aguilar D, Orozco H, et al,. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes. Clin. Exp. Immunol. 2003; 133: 30-7. (Pubitemid 36791939)
143. Manca C, Reed MB, Freeman S, et al,. Differential monocyte activation underlies strain-specific Mycobacterium tuberculosis pathogenesis. Infect. Immun. 2004; 72: 5511-14. (Pubitemid 39223445)
144. Manca C, Tsenova L, Bergtold A, et al,. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β. Proc. Natl Acad. Sci. U. S. A. 2001; 98: 5752-7. (Pubitemid 32435714)
145. Manca C, Tsenova L, Freeman S, et al,. Hypervirulent M. tuberculosis W/Beijing strains upregulate Type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J. Interferon Cytokine Res. 2005; 25: 694-701. (Pubitemid 43010524)
146. Krishnan N, Malaga W, Constant P, et al,. Mycobacterium tuberculosis lineage influences innate immune response and virulence and is associated with distinct cell envelope lipid profiles. PLoS ONE 2011; 6: e23870.
147. Wang C, Peyron P, Mestre O, et al,. Innate immune response to Mycobacterium tuberculosis Beijing and other genotypes. PLoS ONE 2010; 5: e13594.
148. Kato-Maeda K, Shanley CA, Jarlsberg LG, et al,. East-Asian (Beijing) sublineages of Mycobacterium tuberculosis differ in virulence and pathogenicity in the guinea pig. J. Infect. Dis. 2012 (in press).
149. Jeon B, Derrick SC, Lim J, et al,. Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice. Infect. Immun. 2008; 76: 5173-80.
150. Grode L, Seiler P, Baumann S, et al,. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J. Clin. Invest. 2005; 115: 2472-9. (Pubitemid 41266209)
151. Spigelman M, Woosley R, Gheuens J,. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades (Editorial). Int. J. Tuberc. Lung Dis. 2010; 14: 663-4.
152. Burman WJ,. Rip Van Winkle wakes up: development of tuberculosis treatment in the 21st century. Clin. Infect. Dis. 2010; 50: S165-72.
153. TB Alliance. TB Alliance Portfolio. 2011; [Accessed 6 April 2012.] Available from URL:.
154. Koul A, Arnoult E, Lounis N, et al,. The challenge of new drug discovery for tuberculosis. Nature 2011; 469: 483-90.
155. Cole ST, Riccardi G,. New tuberculosis drugs on the horizon. Curr. Opin. Microbiol. 2011; 14: 570-6.
156. Jindani A, Doré CJ, Mitchison DA,. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am. J. Respir. Crit. Care. Med. 2003; 167: 1348-54. (Pubitemid 36609718)
157. Mitchison DA, Selkon JB,. The bactericidal activities of antituberculosis drugs. Am. Rev. Respir. Dis. 1956; 74: 109-16.
158. Mitchison DA,. Basic mechanisms of chemotherapy. Chest 1979; 76: 771-81.
159. Keren I, Minami S, Rubin E, et al,. Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters. Mbio 2011; 2: 100-11.
160. Garton NJ, Waddell SJ, Sherratt AL, et al,. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculosis sputum. PLoS Med. 2009; 5: e75.
161. Burman WJ,. The hunt for the elusive surrogate marker of streilizing activity in tuberculosis treatment. Am. J. Respir. Crit. Care. Med. 2003; 167: 1299-300.
162. Wayne LG, Hayes LG,. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 1996; 64: 2062-9. (Pubitemid 26165667)
163. Voskuil MI, Visconti KC, Schoolnik GK,. Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis 2004; 84: 218-27. (Pubitemid 38857854)
164. Voskuil MI, Schnappinger D, Visconti KC, et al,. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J. Exp. Med. 2003; 198: 705-13. (Pubitemid 37087770)
165. Betts JC, Lukey PT, Robb LC, et al,. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 2002; 43: 717-31. (Pubitemid 34597265)
166. Hu Y, Mangan JA, Dhillon J, et al,. Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J. Bacteriol. 2000; 182: 6358-65.
167. Deb C, Lee C-M DVS, et al,. A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS ONE 2009; 4: e6077.
168. Leistikow RL, Morton RA, Bartek IL, et al,. The Mycobacterium tuberculosis DosR regulon assists in metabolic homeostasis and enables rapid recovery from nonrespiring dormancy. J. Bacteriol. 2010; 192: 1662-70.
169. Bartek IL, Rutherford R, Gruppo V, et al,. The DosR regulon of M. tuberculosis and antibacterial tolerance. Tuberculosis 2009; 89: 310-16.
170. Chao MC, Rubin EJ,. Letting sleeping dos lie: does dormancy play a role in tuberculosis? Annu. Rev. Microbiol. 2010; 64: 293-311.
171. Oliver JD,. Recent findings on the viable but nonculturable state in pathogenic bacteria. FEMS Microbiol. Rev. 2010; 34: 415-25.
172. Sirakova TD, Dubey VS, Deb C, et al,. Identification of a diacylglycerol acyltransferase gene involved in accumulation of triacylglycerol in Mycobacterium tuberculosis under stress. Microbiology 2006; 152: 2717-25. (Pubitemid 44405096)
173. Daniel J, Deb C, Dubey VS, et al,. Induction of a novel class of diacylglycerol acyltransferases and triacylglycerol accumulation in Mycobacterium tuberculosis as it goes into a dormancy-like state in culture. J. Bacteriol. 2004; 186: 5017-30. (Pubitemid 38970829)
174. Daniel J, Maamar H, Deb C, et al,. Mycobacterium tuberculosis uses host triacylglycerol to accumulate lipid droplets and acquires a dormancy-like phenotype in lipid-loaded macrophages. PLoS Pathog. 2011; 7: e1002093.
175. Connolly LE, Edelstein PH, Ramakrishnan L,. Why is long-term therapy required to cure tuberculosis? PLoS Med. 2007; 4: e120.
176. Orme IM,. Development of new vaccines and drugs for TB: limitations and potential strategic errors. Future Microbiol. 2011; 6: 161-77.
177. Mukamolova GV, Turapov O, Malkin J, et al,. Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am. J. Respir. Crit. Care. Med. 2010; 181: 174-80.
178. Young DB, Perkins MD, Duncan K, et al,. Confronting the scientific obstacles to global control of tuberculosis. J. Clin. Invest. 2008; 118: 1255-65. (Pubitemid 351500418)
179. Ekins S, Freundlich JS, Choi I, et al,. Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery. Trends Microbiol. 2011; 19: 65-74.
180. Wang Y, Hess TN, Jones V, et al,. Novel inhibitors of Mycobacterium tuberculosis dTDP-6-deoxy-l-lyxo-4-hexulose reductase (RmlD) identified by virtual screening. Bioorg. Med. Chem. Lett. 2011; 21: 7064-7.
181. Mazandu GK, Nulder NJ,. Generation and analysis of large-scale data-driven Mycobacterium tuberculosis functional networks for drug target identification. Adv. Bioinformatics. 2011; 2011: 801478.
182. Davies GR, Nuermberger EL,. Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs. Tuberculosis 2008; 88 (Suppl. 1): S65-74.
183. Andries K, Gevers T, Lounis N,. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob. Agents Chemother. 2010; 54: 4540-4.
184. Zhang Y,. The magic bullets and tuberculosis drug targets. Annu. Rev. Pharmacol. Toxicol. 2005; 45: 529-64. (Pubitemid 40261816)
185. Sala C, Dhar N, Hartkoorn RC, et al,. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2010; 54: 4150-8.
186. Cho SH, Warit S, Wan B, et al,. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2007; 51: 1380-5. (Pubitemid 46586820)
187. Tsai MC, Chakravarty S, Zhu G, et al,. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell. Microbiol. 2006; 8: 218-32. (Pubitemid 43356045)
188. Flynn JL, Tsenova L, Izzo A, et al,. Experimental models of TB. In:, Kaufmann SHF, Britton WJ, (eds) Handbook of Tuberculosis: Immunology and Cell Biology. Wiley-VCH, Weinheim, 2008; 389-426.
189. Nahid P, Saukkonen J, Kenzie WRM, et al,. Tuberculosis biomarker and surrogate endpoint research roadmap. Am. J. Respir. Crit. Care. Med. 2011; 184: 972-9.